Fresh capital for a kidney diagnostics specialist

Renalytix plc (LSE:RENX) has spent the past few weeks rebuilding its balance sheet. On 3 September 2026 the company announced that it had conditionally raised gross proceeds of £10.1m through a placing and subscription at 6p per share, involving 168,366,151 new ordinary shares. A WRAP retail offer that completed on 8 September added a further £380,142, taking the total to roughly £10.48m. A general meeting followed on 28 September, and the company has since issued a series of holdings notifications and director dealing announcements, including an additional share purchase by its chief executive in mid-September.

What the company does

Renalytix is an artificial intelligence-enabled diagnostics business focused on chronic kidney disease. Its kidneyintelX.dkd test is an FDA-approved, Medicare-reimbursed prognostic test designed to assess early-stage risk in diabetic kidney disease. The shares trade on AIM and on the US OTCQB market. Medicare reimbursement is $950 per reportable result, and the company has said it sees payment on more than 95% of submitted Medicare and Medicare Advantage claims.

Latest developments

Half-year results published on 26 March 2026 for the six months to 31 December 2025 showed revenue of $1.6m, up from $1.3m. Life sciences revenue rose to $0.5m, while commercial test revenue dipped to $1.1m because of the timing of electronic health record integrations. The company added 58 practice sites across New York, Texas, Florida and Arizona and onboarded more than 135 physicians. Fully integrated health record systems rose to five, with eight more under way. In September the company also announced a new accounting reference date and a directorate change.

Financial picture

The operating loss narrowed to $7.1m from $7.5m and the net loss to $8.1m from $8.6m. Cash stood at $6.1m at 31 December 2025, shareholders' funds was negative, and the directors flagged a material uncertainty over going concern. In October 2025, $4m of a convertible bond was converted into shares. At the half-year stage management guided to full-year revenue of about $4m, weighted to the second half. The company does not pay a dividend.

Sector and index context

Renalytix is one of many loss-making healthcare technology companies on the FTSE AIM All Share Index that rely on repeated share raises while they build commercial scale. Small diagnostics businesses must win reimbursement, physician adoption and distribution partners, typically against much larger competitors, and investor appetite for such stories has been selective. Heavy dilution, illustrated by the low placing price, is a common feature of the segment.

Key risks

The going concern warning highlights dependence on external funding and on revenue growth materialising. Test volumes depend on health record integrations and physician behaviour, and the timing of integrations has already held back commercial test revenue. Regulatory, reimbursement and competitive changes in the US could affect pricing, while further share issuance would dilute existing holders. Execution on the further cost reductions that management has promised also matters, as the company's cash burn remains high relative to its current revenue base.

What to watch next

Management has said it aims to conclude a national distribution agreement with a major US diagnostics company during calendar 2026, which would be a significant validation of its commercial model. Other markers include publication of a two-year outcomes study, completion of CE marking for Europe, pharmaceutical trial milestones and evidence that new integrations are lifting testing volumes. Upcoming results under the new accounting reference date will show how far the fresh capital extends the runway.